In addition, GDF11 has anti-inflammatory and antioxidant properties and inhibits cell apoptosis and anti-ageing properties.54–57 Moreover, the GDF11-FTO-PPARγ axis prompted the shift of BMSC commitment to adipocyte and inhibited bone formation during osteoporosis, as a result of the imbalance between bone mass and fat, indicating that m6A “eraser” can affect the function of GDF11 in BMSCs.58 These results indicate that GDF11 may be an important target gene by which to improve the implant success rate in patients with T2DM. The gene discussed is FTO; the disease is osteoporosis.